Skip to content

A Multicenter, Randomized, Controlled Study to Evaluate the Efficacy and Safety of a Dural Sealant in Endoscopic Skull Base Reconstruction

A Multicenter, Randomized, Controlled Study to Evaluate the Efficacy and Safety of a Dural Sealant in Endoscopic Skull Base Reconstruction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113502
Enrollment
Unknown
Registered
2025-11-29
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurological disorders

Interventions

Experimental group:Dura mater medical adhesive
Control group:Standard treatment methods (clinical routine skull base reconstruction approach, but without the use of sealants, such as absorbable dura mater sealing medical adhesives, DuraSeal, and p

Sponsors

Beijing Tiantan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Age >=18 years old, gender not limited. 2) Patients who are scheduled to undergo endoscopic skull base surgery but experience moderate to high flow cerebrospinal fluid leakage during the operation and require skull base reconstruction. 3) The patient and/or the guardian agree to participate in this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Patients with uncontrolled acute infection. 2) Patients with a history of failed skull base reconstruction and persistent CSF leak. 3) Patients with a history of radiotherapy in the operative area. 4) Life expectancy < 3 months. 5) Pregnant or lactating women. 6) Patients with positive HIV antibody screening. 7) Patients with severe liver dysfunction who cannot tolerate the surgery. 8) Patients with uncontrolled severe mental illness, which in the investigator's judgment may affect the subject's compliance or safety. 9) Patients judged by the investigator to have poor compliance and unable to complete the study as required. 10) Patients unable to understand the investigator's introduction or explanation of the study. 11) Other conditions considered by the investigator as unsuitable for participation in the study.

Design outcomes

Primary

MeasureTime frame
Rate of absence of cerebrospinal fluid leak within 1 month postoperatively;

Secondary

MeasureTime frame
No cerebrospinal fluid leakage rate within 3 months after the operation;

Countries

China

Contacts

Public ContactGui Songbai

Beijing Tiantan Hospital, Capital Medical University

guisongbai@yeah.net+86 10 5997 6611

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026